Progeroid syndrome, Petty type
proh-JEER-oid SIN-drohm, PET-ee type
Also known as: Petty progeroid syndrome, Progeroid syndrome with craniosynostosis
At a Glance
What is Progeroid syndrome, Petty type?
Progeroid syndrome, Petty type, is a rare genetic disorder that causes accelerated aging in children. It primarily affects the skin, bones, and connective tissues. The condition is caused by mutations in the SLC25A24 gene, which leads to mitochondrial dysfunction. Over time, affected individuals may experience symptoms like craniosynostosis, which is the premature fusion of skull bones, and hypertrichosis, or excessive hair growth. Early symptoms can include distinct facial features and growth delays, while later symptoms may involve joint stiffness and cardiovascular issues. Early diagnosis is crucial to manage symptoms and improve quality of life. The condition can significantly impact family life due to the need for ongoing medical care and support. Prognosis varies, but many individuals face challenges with mobility and health complications as they age. Daily life for those affected often involves regular medical appointments and therapies to address developmental and physical needs. Supportive care can help manage symptoms and improve life quality. Families may benefit from genetic counseling to understand the condition and its implications. Social support networks can also provide valuable assistance and resources.
Medical Definition
Progeroid syndrome, Petty type, is characterized by a progeroid appearance due to mutations in the SLC25A24 gene, leading to mitochondrial dysfunction. Pathological mechanisms involve impaired energy metabolism and abnormal connective tissue formation. Histological findings often include dysmorphic nuclei and abnormal collagen deposition. It is classified under genetic disorders with a progeroid phenotype. Epidemiologically, it is extremely rare, with only a few cases reported in the literature. The disease course involves progressive physical and developmental challenges, with variability in severity and symptom presentation.
Progeroid syndrome, Petty type Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Progeroid appearance manifests as features resembling premature aging, including wrinkled skin and hair thinning. This is caused by mutations affecting the SLC25A24 gene, leading to mitochondrial dysfunction. Over time, these features become more pronounced, contributing to an aged appearance in young individuals. Daily life is affected as patients may face social challenges and require supportive therapies to manage skin and hair conditions.
Craniosynostosis presents as the premature fusion of skull bones, leading to an abnormal head shape. It results from disrupted signaling pathways during skull development due to genetic mutations. As the child grows, this can lead to increased intracranial pressure and potential developmental delays. Surgical intervention is often necessary to correct skull shape and prevent complications.
Hypertrichosis is characterized by excessive hair growth in areas where hair is normally minimal or absent. This occurs due to hormonal imbalances or genetic factors influencing hair follicle activity. The condition may become more evident with age, leading to cosmetic concerns. Management includes hair removal techniques and counseling to address psychological impacts.
Common
Mitochondrial dysfunction leads to reduced energy production in cells, causing fatigue and muscle weakness. It is a direct result of mutations in the SLC25A24 gene affecting mitochondrial function. Over time, this can lead to progressive muscle degeneration and exercise intolerance. Patients may benefit from energy conservation strategies and nutritional support to manage symptoms.
Developmental delay is observed as slower achievement of milestones compared to peers. It arises from neurological impact due to cranial abnormalities and mitochondrial dysfunction. As the child grows, delays may become more apparent, affecting learning and social interactions. Early intervention programs and tailored educational plans are crucial for support.
Dysmorphic facial features include distinct facial characteristics such as a prominent forehead and wide-set eyes. These features result from abnormal cranial and facial bone development. As the child ages, these features may become more pronounced, affecting self-esteem and social interactions. Cosmetic and reconstructive surgeries can be considered to improve appearance and function.
Less Common
Aortopathy involves abnormalities of the aorta, potentially leading to dilation or aneurysm. This condition is linked to connective tissue defects associated with the syndrome. Over time, it can progress to serious cardiovascular complications if not monitored. Regular cardiovascular assessments and surgical interventions may be necessary to manage risks.
Hearing loss can manifest as partial or complete inability to hear, affecting communication. It may be caused by structural abnormalities in the ear or neurological factors. The condition can worsen over time, impacting language development and social interactions. Hearing aids and speech therapy are important for improving communication abilities.
What Causes Progeroid syndrome, Petty type?
Progeroid syndrome, Petty type, is caused by mutations in the SLC25A24 gene, located on chromosome 1. The SLC25A24 gene encodes a mitochondrial solute carrier protein that is involved in transporting ATP and other nucleotides across the mitochondrial membrane. Mutations in SLC25A24 disrupt the protein's ability to transport these molecules, leading to mitochondrial dysfunction. This dysfunction results in impaired energy production and increased oxidative stress within the cell. As a consequence, cellular metabolism is disrupted, affecting the function of mitochondria-dependent pathways. Neighboring cells and tissues experience a cascade of effects, including increased apoptosis and impaired cellular repair mechanisms. Neuroinflammation is triggered as the immune system responds to cellular damage, further exacerbating tissue degeneration. White matter degeneration occurs due to the loss of oligodendrocytes and myelin, which are particularly sensitive to mitochondrial dysfunction. Symptoms appear in a specific pattern due to the differential vulnerability of tissues to energy deficits and oxidative stress. The severity of the disease varies between patients due to differences in mutation type, genetic background, and environmental factors. Some patients may experience more pronounced craniofacial abnormalities, while others may have more severe neurological symptoms. The variability in symptom presentation can also be attributed to the presence of modifier genes that influence disease expression. Understanding the precise molecular mechanisms of SLC25A24 mutations is crucial for developing targeted therapies. Research continues to explore potential interventions that could mitigate mitochondrial dysfunction and its downstream effects.
How is Progeroid syndrome, Petty type Diagnosed?
Typical age of diagnosis: Progeroid syndrome, Petty type is typically diagnosed in early childhood when characteristic physical features and developmental delays become apparent. Diagnosis often occurs after parents or pediatricians notice unusual growth patterns or physical abnormalities.
The clinician looks for signs of premature aging, craniofacial abnormalities, and growth retardation. A detailed family history is taken to identify any genetic predispositions or similar conditions. Physical examination reveals features such as hypertrichosis, skin changes, and possible craniosynostosis. This step helps to narrow down the differential diagnosis and guides further testing.
Skull X-rays or CT scans are used to assess cranial suture fusion and other skeletal anomalies. Imaging may reveal craniosynostosis and other bone abnormalities consistent with progeroid syndromes. These findings help confirm the diagnosis by correlating clinical features with structural changes. Imaging also helps exclude other conditions such as isolated craniosynostosis or metabolic bone diseases.
Blood tests are ordered to assess metabolic function and rule out other systemic conditions. Biomarkers of mitochondrial dysfunction may be sought, given the association with certain progeroid syndromes. Abnormal results might include elevated lactate or other metabolic indicators. These results guide the clinician towards genetic testing and further metabolic evaluation.
Genetic testing focuses on sequencing the SLC25A24 gene, known to be associated with this condition. Mutations such as de novo variants are identified, confirming the diagnosis of progeroid syndrome, Petty type. These results provide a definitive diagnosis and are crucial for genetic counseling. They also inform family planning and risk assessment for future offspring.
Progeroid syndrome, Petty type Treatment Options
Antioxidants are used to mitigate oxidative stress associated with mitochondrial dysfunction. They work by neutralizing free radicals and reducing cellular damage. Specific drugs may include vitamin E and coenzyme Q10, which have shown some efficacy in clinical studies. However, evidence for their effectiveness is limited and varies between individuals. Side effects are generally mild but can include gastrointestinal discomfort.
Therapists use techniques such as motor skill exercises and balance training to improve physical function. The goal is to enhance mobility, coordination, and overall physical development. Sessions are typically conducted 2-3 times per week, lasting 30-60 minutes each. Outcomes are measured through improvements in motor milestones and functional independence. Long-term benefits include better quality of life and reduced disability.
Surgery is indicated for severe craniosynostosis affecting brain development. The procedure involves reshaping the skull to allow for normal brain growth. Expected benefits include reduced intracranial pressure and improved neurological outcomes. Surgical risks include infection, bleeding, and need for revision surgeries. Post-operative care involves monitoring for complications and ensuring proper wound healing.
The care team includes geneticists, neurologists, physical therapists, and social workers. Interventions focus on managing symptoms, optimizing development, and providing psychosocial support. Strategies include family education on the condition and coping mechanisms. Long-term monitoring involves regular follow-ups to assess growth and development. This comprehensive approach aims to improve overall patient and family well-being.
When to See a Doctor for Progeroid syndrome, Petty type
- Severe chest pain — this could indicate a cardiovascular emergency such as a heart attack or aortic dissection.
- Sudden loss of consciousness — may suggest a serious neurological or cardiovascular event requiring immediate medical attention.
- Acute respiratory distress — indicates potential respiratory failure or severe infection, necessitating urgent intervention.
- Unexplained weight loss — could signify metabolic or systemic issues; consult a healthcare provider for evaluation.
- Progressive difficulty in movement — may indicate worsening of musculoskeletal symptoms, requiring assessment by a specialist.
- Persistent fatigue — can be a sign of mitochondrial dysfunction or other underlying conditions; medical evaluation is recommended.
- Mild joint stiffness — monitor for changes or worsening, and consider gentle exercises to maintain mobility.
- Occasional headaches — track frequency and triggers, and consult a doctor if they become more frequent or severe.
Progeroid syndrome, Petty type — Frequently Asked Questions
Is this condition hereditary?
Progeroid syndrome, Petty type, is primarily caused by de novo mutations, meaning it typically occurs without a family history. The inheritance pattern is not well-defined due to the rarity of the condition. De novo mutations mean the probability of passing it to children is generally low. Carrier status is not applicable as it is not a recessive condition. Genetic counseling is recommended to understand the risks and implications.
What is the life expectancy for someone with this condition?
Life expectancy can vary significantly depending on the severity and age of onset. Early onset often correlates with a poorer prognosis due to rapid progression of symptoms. Mortality is often related to cardiovascular complications or infections. Treatment can improve quality of life and potentially extend survival, though it is primarily supportive. Realistic expectations should include ongoing medical care and monitoring.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, genetic testing, and consultation with specialists such as geneticists and neurologists. The time from first symptoms to diagnosis can vary, often taking several months due to the rarity and complexity of the condition. Delays are common due to overlapping symptoms with other disorders. Genetic testing confirming mutations in relevant genes ultimately confirms the diagnosis. Early referral to a specialist can expedite the process.
Are there any new treatments or clinical trials available?
Research is ongoing, with some promising studies focusing on gene therapy and mitochondrial function. Novel approaches are being explored, though they are still in experimental stages. ClinicalTrials.gov is a resource for finding current trials, and discussing eligibility with your doctor is crucial. Ask your doctor about any new developments and potential participation in trials. New treatments may take years to become widely available, so staying informed is important.
How does this condition affect daily life and activities?
Mobility and self-care can be significantly impacted, requiring adaptive devices or assistance. Educational support may be necessary due to cognitive or physical challenges. Social and emotional challenges are common, necessitating psychological support and community resources. The family may experience increased caregiving demands, highlighting the need for support networks. Adaptations such as physical therapy and occupational therapy can greatly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Is Gorlin-Chaudhry-Moss syndrome associated with aortopathy?
Legué J, François JHM, van Rijswijk CSP et al. · Eur J Cardiothorac Surg · 2020 · PMID: 32355952
- 2.De Novo Mutations in SLC25A24 Cause a Craniosynostosis Syndrome with Hypertrichosis, Progeroid Appearance, and Mitochondrial Dysfunction.
Ehmke N, Graul-Neumann L, Smorag L et al. · Am J Hum Genet · 2017 · PMID: 29100093
- 3.A rare male patient with Fontaine progeroid syndrome caused by p.R217H de novo mutation in SLC25A24.
Rodríguez-García ME, Cotrina-Vinagre FJ, Cruz-Rojo J et al. · Am J Med Genet A · 2018 · PMID: 30329211
- 4.Two sisters resembling Gorlin-Chaudhry-Moss syndrome.
Aravena T, Passalacqua C, Pizarro O et al. · Am J Med Genet A · 2011 · PMID: 21910232
- 5.Gorlin-Chaudhry-Moss syndrome revisited: expanding the phenotype.
Rosti RO, Karaer K, Karaman B et al. · Am J Med Genet A · 2013 · PMID: 23686885
- 6.Different GCMs yet similar outcome: predicting the habitat distribution of Shorea robusta C.F. Gaertn. in the Indian Himalayas using CMIP5 and CMIP6 climate models.
Kaur S, Kaushal S, Adhikari D et al. · Environ Monit Assess · 2023 · PMID: 37221436
- 7.Performance evaluation of CMIP6 climate models for selecting a suitable GCM for future precipitation at different places of Tamil Nadu.
S H, L VR · Environ Monit Assess · 2023 · PMID: 37432481
- 8.Accurate Detection of Dysmorphic Nuclei Using Dynamic Programming and Supervised Classification.
Verschuuren M, De Vylder J, Catrysse H et al. · PLoS One · 2017 · PMID: 28125723
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-14